CRISPR-Cas9 for the Treatment of Transthyretin Cardiac Amyloidosis

Curr Pharm Des. 2023 Dec 6. doi: 10.2174/0113816128267417231127070901. Online ahead of print.NO ABSTRACTPMID:38058090 | DOI:10.2174/0113816128267417231127070901

Source: Current Pharmaceutical Design - December 7, 2023 Category: Drugs & Pharmacology Authors: Giorgia Panichella Alberto Aimo Source Type: research